149 related articles for article (PubMed ID: 35858545)
1. Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes.
Reggiardo RE; Maroli SV; Halasz H; Ozen M; Hrabeta-Robinson E; Behera A; Peddu V; Carrillo D; LaMontagne E; Whitehead L; Kim E; Malik S; Fernandes J; Marinov G; Collisson E; Brooks A; Demirci U; Kim DH
Cell Rep; 2022 Jul; 40(3):111104. PubMed ID: 35858545
[TBL] [Abstract][Full Text] [Related]
2. Transposable element RNA dysregulation in mutant KRAS(G12C) 3D lung cancer spheroids.
Carrillo D; Reggiardo RE; Lim J; Mantalas G; Peddu V; Kim DH
bioRxiv; 2023 Feb; ():. PubMed ID: 36909578
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
Lo A; McSharry M; Berger AH
BMC Cancer; 2022 Dec; 22(1):1315. PubMed ID: 36522653
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
5. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
7. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Ohm AM; Tan AC; Heasley LE; Reyland ME
Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
[TBL] [Abstract][Full Text] [Related]
8. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
Tsuchida N; Murugan AK; Grieco M
Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
[TBL] [Abstract][Full Text] [Related]
9. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
10. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells.
Wang Y; Ngo VN; Marani M; Yang Y; Wright G; Staudt LM; Downward J
Oncogene; 2010 Aug; 29(33):4658-70. PubMed ID: 20562906
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
12. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
13. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
14. KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer.
Pan LN; Ma YF; Li Z; Hu JA; Xu ZH
Cell Biol Int; 2021 Apr; 45(4):795-803. PubMed ID: 33325140
[TBL] [Abstract][Full Text] [Related]
15. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
16. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
18. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
[TBL] [Abstract][Full Text] [Related]
19. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
[TBL] [Abstract][Full Text] [Related]
20. Characterization of KRAS rearrangements in metastatic prostate cancer.
Wang XS; Shankar S; Dhanasekaran SM; Ateeq B; Sasaki AT; Jing X; Robinson D; Cao Q; Prensner JR; Yocum AK; Wang R; Fries DF; Han B; Asangani IA; Cao X; Li Y; Omenn GS; Pflueger D; Gopalan A; Reuter VE; Kahoud ER; Cantley LC; Rubin MA; Palanisamy N; Varambally S; Chinnaiyan AM
Cancer Discov; 2011 Jun; 1(1):35-43. PubMed ID: 22140652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
